Archive for July, 2011

APPY reverse split + updates for ISTA CYTK ANTH

Jul 29, 2011 No Comments by

AspenBio Pharma, Inc. (NASDAQ: APPY), effected today a one for five reverse split of its common shares to ensure continued compliance with NASDAQ minimum bid price rule listing requirements. However it only reduced the number of authorized common shares from 60 million to 30 million. ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) announced top-line results from the […]

Daily News Read more

A look back on predictions made in February of 1H 2011 reverse splits

Jul 29, 2011 No Comments by

On February 14, 2011, I listed about a dozen companies facing delist from NASDAQ or a reverse split to remain listed on NASDAQ during 1H 2011. I now follow up the list by firstly noting my prediction, then what actually happened. (First bracket indicates price as of FEBRUARY 14) – (Second bracket indicates price REVERSE SPLIT […]

Articles Read more


Jul 28, 2011 No Comments by

Horizon Pharma, Inc. (Nasdaq: HZNP) today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a price to the public of $9.00 per share. Its common stock is scheduled to begin trading on The NASDAQ Global Market on July 28, 2011 under the symbol HZNP. Dynavax Technologies Corporation (NASDAQ: […]

Daily News Read more

KERX AEZS complete perifosine enrolment. ADLR data August + AFFY ALXA CYTR

Jul 27, 2011 No Comments

Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research and Development Center, Inc., U.S., today announced that the FDA accepted for review the NDA for peginesatide (formerly known as Hematide) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. Adolor Corporation (NasdaqGM: ADLR) today said it expects to report data […]

Read more


Jul 26, 2011 No Comments

CytRx Corporation (Nasdaq: CYTR) today announced that it intends to offer shares of its common stock and common stock purchase warrants in an underwritten public offering. Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today said that it had met with the European Medicines Agency (EMA) regarding its filing of NUEDEXTA for the treatment of pseudobulbar affect (PBA). […]

Read more

IPO for Horizon Pharma HZNP next week + NEOP NGSX MYRX news

Jul 22, 2011 No Comments

NeurogesX, Inc. (Nasdaq: NGSX), annuounced a private placement of approximately $20m in gross proceeds from the sale of 11,749,552 shares of its common stock and the issuance of five-year warrants to purchase 5,874,782 additional shares of NGSX common stock at an exercise price of $1.65 per share. The purchase price per unit of shares and […]

Read more

RGEN NDA filing possibly delayed. CLSN raises cash + PLX MHAN

Jul 21, 2011 No Comments

Repligen Corporation (NASDAQ: RGEN) today it intends to file its NDA of RG1068 for MRI Imaging of the Pancreas LATER THIS YEAR. In a previous press release it noted that the NDA would be filed LATER THIS SUMMER. This subtle change in wording may suggest that it will not submit its NDA this summer, rather […]

Read more

DVAX misses endpoint. Mergers for PFE ICGN AMAG ALTH. CAPS to delist + SNTA SNSS VVUS

Jul 20, 2011 No Comments

Dynavax Technologies Corporation (NASDAQ: DVAX) today said that top-line data from its Phase 3 trial comparing HEPLISAV, an investigational hepatitis B virus (HBV) vaccine, to a currently marketed HBV vaccine, Engerix-B, demonstrated non-inferiority, superiority and the safety of HEPLISAV. However, it crucially FAILED to reach its primary endpoint of consistency criteria at 8 weeks with […]

Read more

MRNA permission to reverse split. DVAX Phase 3 data to be released Wed

Jul 19, 2011 No Comments

Marina Biotech, Inc (Nasdaq: MRNA) announced after hours yesterday that shareholders had voted to give permission to enforce a reverse split between 1:2 and 1:10. They also voted to increase Authorised Shares from 90m to 180m. Dynavax Technologies Corporation (NASDAQ: DVAX) said it will host a conference call and webcast tomorrow, Wednesday, July 20, 2011, […]

Read more

TLON files Marqibo NDA. NABI fails Phase 3 NicVAX + ALKS CYCC OPTR

Jul 18, 2011 No Comments

Talon Therapeutics, Inc. (OTCBB:TLON) today announced its NDA for Marqibo (vincristine sulfate liposomes injection) was submitted to the FDA seeking accelerated approval of Marqibo in adult Ph-ALL, in second or greater relapse or that has progressed following two or more prior lines of anti-leukemia therapy. Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that NicVAX(R) (Nicotine Conjugate Immunotherapeutic) […]

Read more

TSGEN favourable Adcom vote. PPHM VICL EXEL pipeline updates. PCYC shelf

Jul 15, 2011 No Comments

Futher to the update yesterday, Seattle Genetics (SGEN) announced unanimous recommendations from the FDA Advisory Committee in favour of Accelerated Approval of ADCETRIS(TM) for Post-Transplant Relapsed Hodgkin Lymphoma and Relapsed or Refractory Systemic ALCL. Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) provided an update on its clinical pipeline – – Phase 2 front-line NSCLC trial evaluating bavituximab […]

Read more